Martine E.D. Chamuleau

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · The Lancet · 2021 · 315 citations · Full text

Subcutaneous Epcoritamab, Lymphoid Neoplasia, Dose Escalation +4

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Andrew D. Zelenetz, Gilles Salles, Kylie D. Mason et al. · Blood · 2019 · 133 citations · Full text

A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex

Rogier Q. Hintzen, Rolien de Jong, C. Erik Hack et al. · The Journal of Immunology · 1991 · 126 citations

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

Massimo Federico, María Dolores Caballero Barrigón, Luigi Marcheselli et al. · The Lancet Haematology · 2018 · 112 citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +5

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Kim Linton, Umberto Vitolo, Wojciech Jurczak et al. · The Lancet Haematology · 2024 · 111 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8